Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- NOVARTIS AG
- Publication Date
- 2020-04-03
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
[0001] The present invention relates to the use of mGluR5 antagonists. technical field
[0002] The present invention relates to an mGluR5 antagonist called mavoglurant or a pharmaceutically acceptable salt thereof, for reducing the use of cocaine by patients with cocaine use disorders; and for preventing cocaine use by patients with cocaine use disorders; Use in promoting cocaine abstinence in patients with cocaine use disorder; use in treating symptoms of depression or anxiety associated with cocaine use disorder. In particular, the present invention relates to the use of Mavogulan or a pharmaceutically acceptable salt thereof in reducing cocaine use by cocaine use disorder patients / preventing cocaine use disorder patients from reusing cocaine. Background technique
[0003] Cocaine use disorder is a complex mental disorder defined with reference to DSM-5 criteria (ie, according to the Diagnostic and Statistical Manual of Mental Disorders. 5th Edition, Washington, DC: Ameri...